



Sweetlife Flora Biotech

Production Activation Timeline

From Capital Deployment to Commercial Output

Purpose of This Document

This document outlines the phased activation timeline for Sweetlife Flora Biotech's integrated tissue culture and greenhouse finishing platform, starting from capital deployment and ending in steady commercial production.

The timeline assumes:

- the building and base infrastructure are complete; and
- capital is dedicated exclusively to production capability activation.

The objective is rapid, controlled transition from installation to revenue, not prolonged experimentation.

Timeline Design Principles

The activation plan is built around five execution principles:

1. **Parallelization** – lab and greenhouse activation proceed concurrently
2. **Early Validation** – pilot batches precede scale
3. **Risk Containment** – contamination and loss risks are isolated early
4. **Demand Alignment** – output increases only as sell-through is validated
5. **Capital Velocity** – minimize idle equipment and unused labor

Phase 1: Procurement & Pre-Commissioning

Month 0 – 1

Key Activities:

- finalize equipment specifications and supplier orders
- confirm lab and greenhouse layouts
- recruit lead tissue culture technician / lab manager
- initiate SOP finalization and documentation

Outputs:

- equipment orders placed
- staffing pipeline established
- operational readiness checklist complete

Investor Relevance

This phase locks scope and prevents mid-build changes that create delays or cost overruns.

Phase 2: Installation & Facility Setup**Month 1 – 2****Key Activities:**

- install tissue culture lab equipment and sterile workstations
- install greenhouse benches, environmental systems, and lighting
- configure monitoring and control systems
- receive initial consumables and supplies

Outputs:

- lab and greenhouse physically operational
- systems powered, tested, and calibrated

Investor Relevance

At the end of this phase, capital has been converted into functional production infrastructure.

Phase 3: Commissioning & Validation**Month 2 – 3****Key Activities:**

- begin media preparation and sterile workflow testing
- initiate pilot tissue culture batches
- test acclimatization protocols in greenhouse
- refine SOPs based on observed performance

Outputs:

- validated sterile processes
- baseline contamination and loss metrics
- first successful lab-to-greenhouse transfers

Investor Relevance

This phase de-risks the platform before commercial volumes are attempted.

Phase 4: Initial Commercial Output

Months 3 – 5

Key Activities:

- scale tissue culture batches conservatively
- ramp acclimatization and finishing volumes
- begin limited commercial sales through internal channels
- collect real-time yield, timing, and cost data

Outputs:

- first saleable finished plants
- verified production timelines
- validated unit economics assumptions

Investor Relevance

This is the proof-of-execution phase where biology converts to revenue.

Phase 5: Stabilization & Throughput Optimization

Months 5 – 8

Key Activities:

- optimize batch scheduling and labor allocation
- reduce loss rates through SOP refinement
- increase output to match validated demand
- introduce additional SKUs and genetics

Outputs:

- stabilized production rhythm
- predictable monthly output
- improving margins and efficiency

Investor Relevance

By the end of this phase, the operation behaves as manufacturing, not a startup experiment.

Phase 6: Steady-State Production

Months 8+

Characteristics:

- continuous, demand-aligned production
- stable yields and finishing timelines
- blended channel monetization
- operational data supporting scale decisions

Strategic Optionality:

- capacity expansion
- additional shifts
- replication at additional sites

Timeline Summary (High Level)



Key Risk Controls Embedded in the Timeline

- no full-scale production before validation
- early detection of contamination issues
- staged labor onboarding
- output increases only after sell-through confirmation

This prevents capital burn from outrunning demand or process maturity.

Investor Takeaway

Sweetlife Flora Biotech's production activation timeline is measured in months, not years.

The plan prioritizes:

- speed without recklessness
- validation before scale
- revenue as the confirmation metric

This structure supports rapid capitalization of the \$1.0M raise while maintaining execution discipline